Literature DB >> 28872226

Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.

Durgesh Kumar Dwivedi1, Rajeev Kumar2, Alok Kumar Dwivedi3, Girdhar S Bora2, Sanjay Thulkar4, Sanjay Sharma4, Siddhartha Datta Gupta5, Naranamangalam R Jagannathan1.   

Abstract

BACKGROUND: Risk calculators have traditionally utilized serum prostate-specific antigen (PSA) values in addition to clinical variables to predict the likelihood of prostate cancer (PCa).
PURPOSE: To develop a prebiopsy multiparametric MRI (mpMRI)-based risk score (RS) and a statistical equation for predicting the risk of PCa in biopsy-naive men with serum PSA between 4-10 ng/mL that may help reduce unnecessary biopsies. STUDY TYPE: Prospective cross-sectional study.
SUBJECTS: In all, 137 consecutive men with PSA between 4-10 ng/mL underwent prebiopsy mpMRI (diffusion-weighted [DW]-MRI and MR spectroscopic imaging [MRSI]) during 2009-2015 were recruited for this study. FIELD STRENGTH/SEQUENCE: 1.5T (Avanto, Siemens Health Care, Erlangen, Germany); T1 -weighted, T2 -weighted, DW-MRI, and MRSI sequences were used. ASSESSMENT: All eligible patients underwent mpMRI-directed, cognitive-fusion transrectal ultrasound (TRUS)-guided biopsies. STATISTICAL TESTS: An equation model and an RS were developed using receiver operating characteristic (ROC) curve analysis and a multivariable logistic regression approach. A 10-fold crossvalidation and simulation analyses were performed to assess diagnostic performance of various combinations of mpMRI parameters.
RESULTS: Of 137 patients, 32 were diagnosed with PCa on biopsy. Multivariable analysis, adjusted with positive pathology, showed apparent diffusion coefficient (ADC), metabolite ratio, and PSA as significant predictors of PCa (P < 0.05). A statistical equation was derived using these predictors. A simple 6-point mpMRI-based RS was derived for calculating the risk of PCa and it showed that it is highly predictive for PCa (odds ratio = 3.74, 95% confidence interval [CI]: 2.24-6.27, area under the curve [AUC] = 0.87). Both models (equation and RS) yielded high predictive performance (AUC ≥0.85) on validation analysis. DATA
CONCLUSION: A statistical equation and a simple 6-point mpMRI-based RS can be used as a point-of-care tool to potentially help limit the number of negative biopsies in men with PSA between 4 and 10 ng/mL. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1227-1236.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  diffusion-weighted imaging; magnetic resonance spectroscopic imaging; multiparametric MRI; prostate cancer; risk calculator; statistical model

Mesh:

Substances:

Year:  2017        PMID: 28872226     DOI: 10.1002/jmri.25850

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

Review 1.  Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features.

Authors:  Alok Kumar Dwivedi; Rakesh Shukla
Journal:  Cancer Rep (Hoboken)       Date:  2019-08-22

Review 2.  Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.

Authors:  Durgesh Kumar Dwivedi; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

3.  MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

Authors:  Cong Huang; Gang Song; He Wang; Guangjie Ji; Jie Li; Yuke Chen; Yu Fan; Dong Fang; Gengyan Xiong; Zhongcheng Xin; Liqun Zhou
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

4.  The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A propensity score matching analysis.

Authors:  Hye J Byun; Teak J Shin; Wonho Jung; Ji Y Ha; Byung H Kim; Young H Kim
Journal:  Prostate Int       Date:  2021-11-04

Review 5.  Diagnostic Accuracy of Predictive Models in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mohammad Saatchi; Fatemeh Khatami; Rahil Mashhadi; Akram Mirzaei; Leila Zareian; Zeinab Ahadi; Seyed Mohammad Kazem Aghamir
Journal:  Prostate Cancer       Date:  2022-06-08

Review 6.  Personalized strategies in population screening for prostate cancer.

Authors:  Sebastiaan Remmers; Monique J Roobol
Journal:  Int J Cancer       Date:  2020-06-03       Impact factor: 7.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.